The MDS Beacon™

Lorus Therapeutics Announces Japanese Patent Protection For LOR-2040 – Canadian biopharmaceutical company Lorus Therapeutics announced Wednesday that it now has patent protection in Japan for its cancer-treatment drug LOR-2040.   The drug is currently involved in clinical trials for acute myeloid leukemia and high-risk myelodysplastic syndromes.  For more information, please see the Lorus Therapeutics press release.

Telik Publishes Positive Results Of Telintra In MDS Patients – Telik, Inc., a biopharmaceutical company located in Palo Alto, CA, announced Monday that they published positive results from a Phase 1 clinical trial of Telintra (ezatiostat hydrochloride) in myelodysplastic syndromes (MDS) patients.  Telintra has been shown to improve cytopenias in MDS and chemotherapy patients.  For more information, please see the Telik press release.

Leukemia Cup Regatta – The Sayville Yacht Club in Blue Point, NY will hold its 2009 Leukemia Cup Regatta on August 15 and 16, hosted by the Leukemia & Lymphoma Society (LLS).  The Leukemia Cup Regatta is an annual series of sailing races across the United States to raise money to fight leukemia, lymphoma, and myeloma. Participating sailors race in honor of a community member who has blood cancer. For details, please visit the LLS Web site.

Team In Training Season Kicks Off – The Leukemia & Lymphoma Society’s Team In Training (TNT) program will hold kick-off meetings in Durham, SC and Minnetonka, MN on August 13. Attend the kick-off parties to meet staff, mentors, team members, and patients, or learn more about TNT, the world’s largest endurance sport training program.  All TNT event fundraising supports the Leukemia & Lymphoma Society.   For more information, please see the LLS events page for Durham and Minnetonka.

For a more detailed listing of MDS-related events, please check the MDS Beacon Events Calendar.